Informazione:
Errore:
ID
44718
Descrizione
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer see http://clinicaltrials.gov/ct2/show/study/NCT00661609
collegamento
http://clinicaltrials.gov/ct2/show/study/NCT00661609
Keywords
versioni (4)
- 21/11/11 21/11/11 -
- 27/03/14 27/03/14 - Martin Dugas
- 17/09/21 17/09/21 -
- 27/09/21 27/09/21 - Sarah Riepenhausen
Titolare del copyright
AstraZeneca
Caricato su
27 settembre 2021
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
A Phase II Study of AZD4877 (a Novel Anti-mitotic DRKS00004052
Eligibility Bladder Cancer NCT00661609
- StudyEvent: Eligibility
Similar models
Eligibility Bladder Cancer NCT00661609
- StudyEvent: Eligibility
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Urothelial cancer
Item
Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra).
boolean
C1519840 (UMLS CUI [1])
Stage IV
Item
Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by curative surgery and/or curative radiotherapy
boolean
C0441772 (UMLS CUI-1)
Prior chemotherapy
Item
Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting.
boolean
C1514457 (UMLS CUI-1)
Selfcare
Item
Ambulatory and capable of all selfcare more than 50% of waking hours
boolean
C0036592 (UMLS CUI-1)
Prior treatment
Item
Prior treatment with investigational or standard anti-cancer agents, including radiotherapy, within 4 weeks prior to first dose of study medication; 6 weeks if prior systemic mitomycin, nitrosourea, or suramin.
boolean
C1514463 (UMLS CUI-1)
Bone marrow
Item
Inadequate bone marrow reserve
boolean
C0005953 (UMLS CUI-1)
Liver function
Item
Inadequate liver function in the presence of liver metastases
boolean
C0232744 (UMLS CUI)
Renal function
Item
Impaired renal function
boolean
C1565489 (UMLS CUI)